SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools announced the sale of its Mass Cytometry business to…

Standard BioTools Inc. · PRESS-RELEASE filed Jul 28, 2026 at 08:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jul 28, 2026 at 08:00 ET

Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio for up to $10M, received ~$30M from Illumina to buy out earnout/royalty obligations, and secured early HSR termination for its pending merger with Treeline Biosciences. These actions strengthen the balance sheet, reduce contingent liabilities, and de-risk the Treeline merger, which is expected to close by year-end 2026.

  • Sale of Mass Cytometry business to Multiplex Bio for up to $10 million (seller's note + milestone payment)
  • Received approximately $30 million from Illumina to buy out 2026 earnout and all future royalty payments related to the SomaLogic acquisition
  • U.S. FTC granted early termination of HSR waiting period for the Treeline merger
  • Treeline merger and Mass Cytometry sale expected to close by end of 2026, subject to stockholder approval and customary conditions

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access